A drug that has the ability to ‘transform the landscape’ for people living with metastatic colorectal cancer (CRC) has been granted priority review by the US Food and Drug Administration (FDA).
Thermo Fisher Scientific will partner with AstraZeneca and the University of Nebraska Medical Center to advance biomarker discovery and characterization.
Project ALS has selected Medidata’s biomarker discovery solution for its research projects, aiming to improve understanding of the ALS disease process and develop new therapeutic strategies.
Freenome’s multiomics platform is being used in a Phase II clinical trial to help identify patients most likely to respond to ADC Therapeutics’ antibody drug conjugate.
Caprion Biosciences and HistoGeneX join forces, combining the two businesses to provide a source for immune monitoring, protein characterization, and tissue pathology solutions, as immunotherapy landscape evolves.
To further support Asia-Pacific oncology trials, NeoGenomics opens new Singapore-based pharma services laboratory in the same building as PPD Laboratories’ central lab.
Improving the prognostic value of early phase data is among one of several ways to increase the probability of successes in drug development, a process which has become more expensive as failure rates have risen, says an industry expert.
Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.
Biomarkers have the potential to improve drug development productivity by 34% over the next five years, during which period pre-screened patient pools and the application of predictive analytics also will help address the increasing complexity of clinical...
Medidata’s machine learning-based solution revealed novel biomarkers for Castleman disease among other discoveries that could help accelerate diagnosis and treatment.
Quanterix is expanding its biomarker technology platform to oncology with the launch of a new test bed for up to 10-plex assays, which will enable drug developers to expedite clinical trials, says CEO.